For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- BUSINESS NEWS IN BRIEF
February 18, 2002
- Medical Device Federation Requests Regulatory Reforms
February 18, 2002
- FDA Is Very Interested in Immediate PMS System: Dr Kurokawa of PFSB
February 18, 2002
- Korosho to Accept STED-based Applications for Medical Devices
February 18, 2002
- Korosho to Allow Hospitals to Charge Special Medical Treatment Fee for Unlisted Drugs
February 18, 2002
- Court Rejects Taisho's Demands in Lawsuit Against Daikoku
February 18, 2002
- Legal Drug Classification to Be Revised
February 18, 2002
- 49% Rise in Operating Profits Expected for Ain Pharmaciez: Nomura Report
February 18, 2002
- EAD Director Calls on Makers to Reduce Invoice Prices
February 18, 2002
- Sugi Pharmacy's Ordinary Profits to Jump 40%: Okasan Securities
February 18, 2002
- Safety Measures Must Be Coordinated with Global Standards: Korosho Official
February 18, 2002
- Tokai Tokyo Research Forecasts Continued Growth for Matsumotokiyoshi
February 18, 2002
- Requirements for Biologic Products, Antibiotics Revised
February 18, 2002
- RESEARCH AND DEVELOPMENT NEWS IN BRIEF
February 18, 2002
- 30% Hike of Copayment Agreed
February 18, 2002
- Korosho to Review Drug Reevaluation System
February 18, 2002
- WORLD NEWS IN BIREF
February 18, 2002
- Hayashibara's IFN-a to Be Approved in South Korea
February 18, 2002
- REGULATORY NEWS IN BRIEF
February 18, 2002
- Japanese Global Strategy Update (7)
February 18, 2002
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…